The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Randomized Trial of Icatibant in ACE-Inhibitor–Induced Angioedema
Open accessAbstract
BACKGROUND: Angioedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts for one third of angioedema cases in the emergency room; it is usually manifested in the upper airway and the head and neck region. There is no approved treatment for this potentially life-threatening condition. METHODS: In this multicenter, double-blind, double-dummy, randomized phase 2 study, we assigned patients who had ACE-inhibitor-induced angioedema of the upper aerodigestive tract to treatment with 30 mg of subcutaneous icatibant, a selective bradykinin B2 receptor antagonist, or to the current off-label standard therapy consisting of intravenous prednisolone (500 mg) plus clemastine (2 mg). The primary efficacy end point was the median time to complete resolution of edema. RESULTS: All 27 patients in the per-protocol population had complete resolution of edema. The median time to complete resolution was 8.0 hours (interquartile range, 3.0 to 16.0) with icatibant as compared with 27.1 hours (interquartile range, 20.3 to 48.0) with standard therapy (P=0.002). Three patients receiving standard therapy required rescue intervention with icatibant and prednisolone; 1 patient required tracheotomy. Significantly more patients in the icatibant group than in the standard-therapy group had complete resolution of edema within 4 hours after treatment (5 of 13 vs. 0 of 14, P=0.02). The median time to the onset of symptom relief (according to a composite investigator-assessed symptom score) was significantly shorter with icatibant than with standard therapy (2.0 hours vs. 11.7 hours, P=0.03). The results were similar when patient-assessed symptom scores were used. CONCLUSIONS: Among patients with ACE-inhibitor-induced angioedema, the time to complete resolution of edema was significantly shorter with icatibant than with combination therapy with a glucocorticoid and an antihistamine. (Funded by Shire and the Federal Ministry of Education and Research of Germany; ClinicalTrials.gov number, NCT01154361.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACE Inhibitor???Induced Angioedema: Incidence, Prevention and Management
Vleeming, W., van Amsterdam, J. G. C., Stricker, B. H., & de Wildt, D. J. (1998) · Drug Safety · doi:10.2165/00002018-199818030-00003 · Cited by 243
Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors
Miller, D. R., Oliveria, S. A., Berlowitz, D. R., Fincke, B. G., Stang, P., & Lillienfeld, D. E. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.110270 · Cited by 238
Cited by
Maurer, M., Magerl, M., Ansotegui, I., Aygören‐Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A. S., et al. (2018) · Allergy · doi:10.1111/all.13384 · Cited by 513
Arendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
Metadata
- Authors
- Baş, M., Greve, J., Stelter, K., Havel, M., Strassen, U., Rotter, N., Veit, J., Schossow, B., Hapfelmeier, A., Kehl, V., Kojda, G., & Hoffmann, T. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-29
- Volume
- 372
- Issue
- 5
- Pages
- 418-425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166848757
- Cited by
- 253
- References
- 2
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Trial of Icatibant in ACE-Inhibitor–Induced Angioedema. https://app.cochat.ai/papers/10.1056/nejmoa1312524
- The paper
- Baş, M., Greve, J., Stelter, K., Havel, M., Strassen, U., Rotter, N., Veit, J., Schossow, B., Hapfelmeier, A., Kehl, V., Kojda, G., & Hoffmann, T. K. (2015). A Randomized Trial of Icatibant in ACE-Inhibitor–Induced Angioedema. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1312524
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.